|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Endocyte, Inc. (ECYT) Secures DOXIL® Supply to Support Ongoing Phase 3 PROCEED Trial in Ovarian Cancer
8/2/2012 9:54:58 AM
WEST LAFAYETTE, Ind., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company has secured DOXIL® (doxorubicin HCl liposome injection) supply from Janssen Products, LP, to supplement existing supply already in place to support the ongoing Phase 3 PROCEED trial in ovarian cancer. The PROCEED trial compares vintafolide in combination with DOXIL versus DOXIL alone for the treatment of folate-receptor positive platinum resistant ovarian cancer.
|
|
|
|
|
|
|
|
|
|
|